State Street Corp Has $59.33 Million Position in Amicus Therapeutics, Inc. (FOLD)
State Street Corp increased its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 2.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,892,564 shares of the biopharmaceutical company’s stock after purchasing an additional 125,635 shares during the quarter. State Street Corp owned approximately 3.58% of Amicus Therapeutics worth $59,332,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. Teacher Retirement System of Texas grew its stake in shares of Amicus Therapeutics by 1.7% in the second quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 169 shares during the last quarter. DORCHESTER WEALTH MANAGEMENT Co bought a new stake in Amicus Therapeutics during the second quarter valued at $111,000. Tudor Investment Corp ET AL bought a new stake in Amicus Therapeutics during the second quarter valued at $124,000. Aperio Group LLC boosted its position in Amicus Therapeutics by 13.5% during the second quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock valued at $141,000 after acquiring an additional 1,663 shares during the last quarter. Finally, Zacks Investment Management bought a new stake in Amicus Therapeutics during the second quarter valued at $145,000.
Amicus Therapeutics, Inc. (NASDAQ FOLD) opened at 14.24 on Wednesday. The stock’s 50 day moving average is $14.35 and its 200-day moving average is $11.46. The company’s market cap is $2.34 billion. Amicus Therapeutics, Inc. has a 52-week low of $4.41 and a 52-week high of $16.60.
Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.03. The firm had revenue of $7.16 million for the quarter, compared to analyst estimates of $6.96 million. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. During the same quarter in the previous year, the firm posted ($0.40) EPS. Equities research analysts predict that Amicus Therapeutics, Inc. will post ($1.32) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “State Street Corp Has $59.33 Million Position in Amicus Therapeutics, Inc. (FOLD)” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://theolympiareport.com/2017/11/01/state-street-corp-has-59-33-million-position-in-amicus-therapeutics-inc-fold.html.
In other news, CEO John F. Crowley sold 449,295 shares of Amicus Therapeutics stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $14.33, for a total transaction of $6,438,397.35. Following the sale, the chief executive officer now owns 380,723 shares of the company’s stock, valued at approximately $5,455,760.59. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Daphne Quimi sold 7,000 shares of Amicus Therapeutics stock in a transaction dated Thursday, October 12th. The shares were sold at an average price of $14.25, for a total transaction of $99,750.00. The disclosure for this sale can be found here. Insiders have sold a total of 628,224 shares of company stock worth $9,024,003 in the last ninety days. Insiders own 3.40% of the company’s stock.
A number of brokerages have commented on FOLD. Leerink Swann reaffirmed a “buy” rating and set a $20.00 price target (up previously from $17.00) on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Robert W. Baird reaffirmed an “outperform” rating and set a $16.00 price target on shares of Amicus Therapeutics in a research report on Monday, September 25th. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $15.00 price target (up previously from $13.00) on shares of Amicus Therapeutics in a research report on Wednesday, August 9th. Cowen and Company reaffirmed a “buy” rating and set a $16.00 price target on shares of Amicus Therapeutics in a research report on Monday, August 14th. Finally, Zacks Investment Research cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 12th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $17.81.
Amicus Therapeutics Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.